← All comparisons
Head-to-head · FAERS comparison

Clopidogrel vs Apixaban: side effects in FDA adverse event reports

How to read this page. FAERS report counts have no denominator; the comparison is of reporting patterns, not of risk. Signals are screened against each FDA label (badges) but not causally assessed. Not medical advice.

At a glance

ClopidogrelApixaban
Drug class–Factor Xa Inhibitor
Brand names––
FAERS reports197,00066,516
Serious81%96%
Death outcome21,7797,220
Boxed warningYes DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS The effectiveness of clopidogrel is dependent on its activation to an active metabolite by the cytochrome P450 (CYYes WARNING: (A) PREMATURE DISCONTINUATION OF APIXABAN INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF APIXABA

Signals both drugs share

No strong shared signal after removing coding and lab terms.

Labeled signals distinctive to Clopidogrel

Labeled signals distinctive to Apixaban

Common questions

Which has more reported side effects, Clopidogrel or Apixaban?

Clopidogrel has 197,000 FAERS reports and Apixaban 66,516. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (81% vs 96%) is a better like-for-like signal of the kind of problems reported.

Which side effects do Clopidogrel and Apixaban share?

They share no strong flagged signal after artifacts and lab terms are removed.

Is Clopidogrel or Apixaban safer?

FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.